Ongoing clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events, no ...
Invivyd had also attempted to attain regulatory approval for pemivibart.Credit: Design_Cells via Shutterstock. At IDWeek 2025, (the joint annual meeting of the Infectious Diseases Society of America, ...
The updated NCCN Guidelines now include the recommendation for monoclonal antibodies for pre-exposure prophylaxis against COVID-19, highlighting the significance of Invivyd's products in cancer care.
Invivyd's monoclonal antibody (mAb) VYD2311 is a prophylactic for COVID has greater efficacy and less side effects than COVID vaccines. The current administration's clear goal of minimizing the ...
Interim data captured from a phase 3 trial suggest pemivibart may be effective prophylaxis against COVID-19 infection for high-risk patients with significant immunocompromising conditions who continue ...
New FDA approval language for COVID-19 vaccines is sowing confusion about which conditions put people at greater risk for severe disease and who can avoid the inconvenience and cost of off-label ...
Phase 2 clinical trial will evaluate the safety, translational biology, and exploratory clinical efficacy of VYD2311 in people with Long COVID or ...
Looking for information about the FDA’s limited approval of 2025-26 COVID vaccines? Read what we know about who can get an updated COVID shot this year. Updated Aug. 27 If it feels like several people ...
Most people have put the COVID-19 pandemic behind them. Infections, vaccinations, or a combination of both have bolstered people's immunity, and while new variants continue to pop up, getting sick ...
A new clinical trial found azelastine cut COVID-19 infections by 70%, hinting at a cheap, accessible way to add protection alongside vaccines. Let’s be honest: when it comes to COVID-19 prevention, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results